Maegim한국어

에이프로젠

007460KOSPISector: Pharma & Biotech
₩2,175 0.46%Market cap ₩51.3BAs of Jul 21, 2026 close · updated once daily
C
Grade C40.2 ptsTop 70% of 2,523 stocks
Financial strength
28.7
Growth momentum
45.8
Price attractiveness
49.2

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

28.7
How much debt does it carry relative to equity?
Debt-to-equity ratio
56.4%
Below median · Top 54.3% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
97.2%
Below median · Top 77% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-81.0%
Below median · Top 72.2% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-44.3%
Below median · Top 81.9% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original

2

Growth momentum

45.8
How much did revenue grow in a year?
Revenue growth (YoY)
-21.4%
Below median · Top 89.3% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
14.6%
Above median · Top 21.2% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-10.1%
Below median · Top 63.6% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
19.9%
Above median · Top 42.7% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original

3

Price attractiveness

49.2
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Below median · Top 98.6% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.32x
Above median · Top 3% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15